Truist raises Vericel stock price target on MACI growth momentum

Truist raised its Vericel price target to $65 from $52 and maintained a Buy rating after strong third-quarter results, including record MACI activity and upside in Burn Care, profitability, and free cash flow. Vericel reported $85.37 million in quarterly revenue, up 26% year over year and about 9.5% above projections, and EPS of $0.27 versus $0.06 consensus; shares gained 28.6% over the past week. Truist expects MACI growth above 20% in 2026 and 2027, citing higher estimates and accelerating profitability and free cash flow.

Analysis

The key underwriting question is whether leading indicators—surgeon additions and biopsies—convert into sustained MACI implants and repeatable revenue, not whether one quarter beat estimates. Those activity measures may precede revenue, so the next few quarters should reveal whether the adoption funnel is widening or merely pulling demand forward. A strong conversion rate would support operating leverage and make premium revenue valuation more durable; weaker conversion would leave the stock exposed to multiple compression even if revenue remains healthy.

Near term, the 28.6% weekly rally and proximity to the 52-week high raise the bar for incremental buyers. The $65 target is a sell-side scenario based on 2028 estimates and a 7x EV/revenue multiple, not independent evidence that the market has validated those assumptions. Over 1–3 months, focus on management’s updated growth outlook and whether MACI activity translates into implants, alongside cash generation. Over 6–18 months, manufacturing throughput, reimbursement/access, and the pace of surgeon adoption are the structural swing factors. Alternative cartilage-repair approaches could constrain adoption, but the article provides no evidence of a current share shift. The bullish thesis is falsified by slowing implant growth despite continued surgeon additions, weaker cash conversion, or guidance that no longer supports sustained high-teens-plus growth.

Key Decisions for Investors

• Do not chase the post-earnings gap as a fresh outright long. For existing holders, consider trimming into strength or retaining a core position while waiting for implant-conversion evidence; the upside case depends on execution catching up with an already elevated expectation set.
• Watch the next quarterly report for MACI implants relative to surgeon additions and biopsies, plus free-cash-flow conversion. Improving conversion supports the premium-growth thesis; a widening activity-to-implant gap is an early warning to reduce exposure.
• For investors seeking defined risk, consider a call spread only after implied volatility and option pricing are checked; avoid paying up for naked calls after the sharp rally. The thesis is invalidated by a material growth-outlook reset or clear deterioration in implant momentum.
• No company-specific short is warranted on the supplied evidence. Reassess if growth disappoints while the valuation still embeds a premium multiple; verify current enterprise value, forward revenue estimates, and valuation versus comparable medtech names before sizing any relative-value trade.